You might assume that cancer research money follows the death toll — that the deadliest cancers draw the most funding. The real picture is more tangled, and it has fueled a long-running debate about fairness.
Consider prostate and breast cancer, which kill comparable numbers of Americans each year. According to figures from the National Institutes of Health, between 2008 and 2023 the government spent roughly 2.5 times more on breast cancer research than on prostate — about $700 million a year versus $270 million. Advocates for men’s health have pointed to that gap for years.
But dollars-per-death tells a different story. A 2026 analysis in JAMA Network Open found that, measured against how many lives each cancer takes, the deadliest cancers are actually the least funded. Prostate and breast cancer, both with high survival rates, came out comparatively well-resourced, while pancreatic and small-cell lung cancers — which kill most of the people they strike — received far less per death.
The pattern, researchers note, reflects more than need. Funding also follows scientific opportunity, the strength of patient advocacy, and how common a cancer is. According to the same analysis, cancers such as bladder, liver, esophageal, and stomach — less famous, and with fewer champions — consistently rank among the most underfunded relative to the burden they impose.
Allyson Good curates senior living, health, and family content. She is formerly the Managing Editor of Active Life, a print newspaper published in 2016-2017 for seniors, choosing practical articles on health, money, safety, and everyday living for older readers. She is also an avid gardener and offers up Garden Hints and Tips on a regular basis.
